Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells

• Main Authors: Eskew Jeffery D, Sadikot Takrima, Morales Pedro, Duren Alicia, Dunwiddie Irene, Swink Megan, Zhang Xiaoying, Hembruff Stacey, Donnelly Alison, Rajewski Roger A, Blagg Brian SJ, Manjarrez Jacob R, Matts Robert L, Holzbeierlein Jeffrey M, Vielhauer George A
• Format: Article
• Language: English
• Published: BMC 2011-10-01
• Series: BMC Cancer
• Subjects: Hsp90; prostate cancer; novobiocin; C-terminal inhibitors; N-terminal inhibitors
• Online Access: http://www.biomedcentral.com/1471-2407/11/468

<p>Abstract</p> <p>Background</p> <p>The molecular chaperone, heat shock protein 90 (Hsp90) has been shown to be overexpressed in a number of cancers, including prostate cancer, making it an important target for drug discovery. Unfortunately, results with <it>N-</it>terminal inhibitors from initial clinical trials have been disappointing, as toxicity and resistance resulting from induction of the heat shock response (HSR) has led to both scheduling and administration concerns. Therefore, Hsp90 inhibitors that do not induce the heat shock response represent a promising new direction for the treatment of prostate cancer. Herein, the development of a C-terminal Hsp90 inhibitor, KU174, is described, which demonstrates anti-cancer activity in prostate cancer cells in the absence of a HSR and describe a novel approach to characterize Hsp90 inhibition in cancer cells.</p> <p>Methods</p> <p>PC3-MM2 and LNCaP-LN3 cells were used in both direct and indirect <it>in vitro </it>Hsp90 inhibition assays (DARTS, Surface Plasmon Resonance, co-immunoprecipitation, luciferase, Western blot, anti-proliferative, cytotoxicity and size exclusion chromatography) to characterize the effects of KU174 in prostate cancer cells. Pilot <it>in vivo </it>efficacy studies were also conducted with KU174 in PC3-MM2 xenograft studies.</p> <p>Results</p> <p>KU174 exhibits robust anti-proliferative and cytotoxic activity along with client protein degradation and disruption of Hsp90 native complexes without induction of a HSR. Furthermore, KU174 demonstrates direct binding to the Hsp90 protein and Hsp90 complexes in cancer cells. In addition, in pilot <it>in-vivo </it>proof-of-concept studies KU174 demonstrates efficacy at 75 mg/kg in a PC3-MM2 rat tumor model.</p> <p>Conclusions</p> <p>Overall, these findings suggest C-terminal Hsp90 inhibitors have potential as therapeutic agents for the treatment of prostate cancer.</p>